Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 15;8(5):416-26.
doi: 10.4251/wjgo.v8.i5.416.

MicroRNA in rectal cancer

Affiliations
Review

MicroRNA in rectal cancer

Azadeh Azizian et al. World J Gastrointest Oncol. .

Abstract

In rectal cancer, one of the most common cancers worldwide, the proper staging of the disease determines the subsequent therapy. For those with locally advanced rectal cancer, a neoadjuvant chemoradiotherapy (CRT) is recommended before any surgery. However, response to CRT ranges from complete response (responders) to complete resistance (non-responders). To date we are not able to separate in advance the first group from the second, due to the absence of a valid biomarker. Therefore all patients receive the same therapy regardless of whether they reap benefits. On the other hand almost all patients receive a surgical resection after the CRT, although a watch-and-wait procedure or an endoscopic resection might be sufficient for those who responded well to the CRT. Being highly conserved regulators of gene expression, microRNAs (miRNAs) seem to be promising candidates for biomarkers. Many studies have been analyzing the miRNAs expressed in rectal cancer tissue to determine a specific miRNA profile for the ailment. Unfortunately, there is only a small overlap of identified miRNAs between different studies, posing the question as to whether different methods or differences in tissue storage may contribute to that fact or if the results simply are not reproducible, due to unknown factors with undetected influences on miRNA expression. Other studies sought to find miRNAs which correlate to clinical parameters (tumor grade, nodal stage, metastasis, survival) and therapy response. Although several miRNAs seem to have an impact on the response to CRT or might predict nodal stage, there is still only little overlap between different studies. We here aimed to summarize the current literature on rectal cancer and miRNA expression with respect to the different relevant clinical parameters.

Keywords: Chemoradiotherapy; Expression; MicroRNA; Polymorphism; Rectal cancer; Response.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Differential expression of microRNAs in rectal cancer. The differentially expressed microRNAs (miRNAs) in rectal cancer compared to normal rectal tissue are listed, sorted by studies, respectively. The correlating circles show the number of differentially expressed miRNAs in the mentioned studies and point out the number of miRNAs overlapping between those studies.
Figure 2
Figure 2
Differential expression of miRNAs dependent on response to preoperative chemoradiotherapy. miRNAs in up arrow callouts are significantly higher expressed; those in down arrow callouts are significantly lower expressed. On the left site there are miRNAs, isolated from pretherapeutic biopsies, which are supposed to predict response or non-response, respectively. The miRNAs in the bottom localized on the right side, are found to be significantly higher or lower expressed in post-therapeutic tumor biopsies of non-responders after chemoradiotherapy compared to pretherapeutic biopsies. 1Lopes-Ramos et al[69], 2014; 2Hotchi et al[68], 2013; 3Della Vittoria Scarpati et al[66], 2012; 4Bhangu et al[70], 2014; 5Svoboda et al[64], 2012; 6Svoboda et al[63], 2008; 7Drebber et al[65], 2011.

References

    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403. - PubMed
    1. Zhu W, Xu B. MicroRNA-21 identified as predictor of cancer outcome: a meta-analysis. PLoS One. 2014;9:e103373. - PMC - PubMed
    1. Kalady MF, Sanchez JA, Manilich E, Hammel J, Casey G, Church JM. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis Colon Rectum. 2009;52:1039–1045. - PubMed
    1. Slattery ML, Levin TR, Ma K, Goldgar D, Holubkov R, Edwards S. Family history and colorectal cancer: predictors of risk. Cancer Causes Control. 2003;14:879–887. - PubMed
    1. Alexander DD, Miller AJ, Cushing CA, Lowe KA. Processed meat and colorectal cancer: a quantitative review of prospective epidemiologic studies. Eur J Cancer Prev. 2010;19:328–341. - PubMed